Current and future burden from Lyme disease in Québec as a result of climate change.
- Published in:
- Canada Communicable Disease Report, 2023, v. 49, n. 10, p. 446, doi. 10.14745/ccdr.v49i10a06
- By:
- Publication type:
- Article
Works matching IS 11884169 AND DT 2023 AND VI 49 AND IP 10
Results: 7
1
2
Characteristics and clinical outcomes of nirmatrelvir/ritonavir (PaxlovidTM) recipients in Canada, 2022: a descriptive cohort study.
- Published in:
- Canada Communicable Disease Report, 2023, v. 49, n. 10, p. 440, doi. 10.14745/ccdr.v49i10a05
- By:
- Publication type:
- Article
3
Infectious syphilis and congenital syphilis in Canada, 2022*.
- Published in:
- Canada Communicable Disease Report, 2023, v. 49, n. 10, p. 439
- Publication type:
- Article
4
Influenza vaccines may protect against cardiovascular diseases: The evidence is mounting and should be known by the Canadian public health community.
- Published in:
- Canada Communicable Disease Report, 2023, v. 49, n. 10, p. 433, doi. 10.14745/ccdr.v49i10a04
- By:
- Publication type:
- Article
5
Healthcare costs and effects of post-COVID-19 condition in Canada.
- Published in:
- Canada Communicable Disease Report, 2023, v. 49, n. 10, p. 425, doi. 10.14745/ccdr.v49i10a03
- By:
- Publication type:
- Article
6
National Influenza Annual Report, Canada, 2022-2023: Canada's first fall epidemic since the 2019-2020 season.
- Published in:
- Canada Communicable Disease Report, 2023, v. 49, n. 10, p. 413, doi. 10.14745/ccdr.v49i10a02
- By:
- Publication type:
- Article
7
Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2023-2024.
- Published in:
- Canada Communicable Disease Report, 2023, v. 49, n. 10, p. 406, doi. 10.14745/ccdr.v49i10a01
- By:
- Publication type:
- Article